Expression of MiR-130a in Serum Samples of Patients with Epithelial Ovarian Cancer and Its Association with Platinum Resistance

CHEN Cen, Wang Hong-jing, Yang Ling-yun. et al

Abstract

To determine the expression of miR-130a in patients with epithelial ovarian cancer and its association with platinum resistance. Methods 32 patients with platinum resistance and 30 patients without platinum resistance were recruited in this study. Real-time PCR was performed to detect the expression of miR-130a in the serum samples of the patients. ELISA was used to measure the expression level of phosphatase and tensin homolog deleted on chromosome ten (PTEN) and B-cell lymphoma-2 (BCL-2). Results Platinum-resistant patients had significantly higher levels of expression of miR-130a and BCL-2, and lower level of PTEN than platinum-sensitive patients （P<0.05）. The expression level of miR-130a increased with increased severity in histological classification and appearance of lymph node metastasis in the platinum-resistant patients (P<0.05).Conclusion MiR-130a may mediate the generation of platinum resistance in epithelial ovarian cancer through inhibiting PTEN to activate PI3K/AKT signaling pathway and increasing BCL-2 to inhibit tumor cell apoptosis. MiR-130a may be a new potential target of gene therapy in platinum-resistant ovarian cancers.

 

Keywords: Ovarian cancer, Platinum resistance, MiR-130a, Mechanism 

 

Full Text:

PDF


References


Hennessy ВТ. Coleman R, Markman M. Ovarian cancer. Lancet.2009;374(9698): 1371-1382.

Muggia F. Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer. Gynecol Oncol,2009; 112( 1):275-281.

Rabik С A, Dolan MP3. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2007;33(1):9-23.

Yang L. Li N. Wang H. el at. Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDRl/P-glycoprotein-mediated drug resistance. Oncol Rep,2012;28(2) ;592-600.

Chen X, Ba Y, Ma L. et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res.2008; 18( 10);997-1006.

Corney DC. Flesken-Nikitin A. Godwin AK. Et al. MicroRNA- 34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res,2007;67(18) s8433-8438.

Fu X. Tian J, Zhang L. et al. Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells. FEBS Lett,2012;586(9); 1279-1286.

Xia H. Ooi LL, Hui KM. MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Hepatology, 2013;58(2) s 629-641.

Rao E. Jiang С. Ji M, et al, The miRNA-17 approximately 92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. Leukemia,2012;26(5):1064-1072.

Chao A, Lai CH, Chen HC, et al. Serum microRNAs in clear cell carcinoma of the ovary. Taiwan J Obstet Gynecol. 2014 ;53 (4):536-541.

Carracedo A, Alimonti A, Pandolfi PP. PTEN level in tumor suppression: how much is too little? Cancer Res. 2011; 71 (3): 629-633.


Refbacks

  • There are currently no refbacks.